These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 34727953)

  • 1. Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma.
    Cioce M; Canino C; Pass H; Blandino G; Strano S; Fazio VM
    J Exp Clin Cancer Res; 2021 Nov; 40(1):344. PubMed ID: 34727953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.
    di Martino S; Amoreo CA; Nuvoli B; Galati R; Strano S; Facciolo F; Alessandrini G; Pass HI; Ciliberto G; Blandino G; De Maria R; Cioce M
    Oncogene; 2018 Mar; 37(10):1369-1385. PubMed ID: 29311642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into Intra-Tumoral Heterogeneity: Transcriptional Profiling of Chemoresistant MPM Cell Subpopulations Reveals Involvement of NFkB and DNA Repair Pathways and Contributes a Prognostic Signature.
    Cioce M; Sacconi A; Pass HI; Canino C; Strano S; Blandino G; Fazio VM
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.
    Cioce M; Ganci F; Canu V; Sacconi A; Mori F; Canino C; Korita E; Casini B; Alessandrini G; Cambria A; Carosi MA; Blandino R; Panebianco V; Facciolo F; Visca P; Volinia S; Muti P; Strano S; Croce CM; Pass HI; Blandino G
    Oncogene; 2014 Nov; 33(46):5319-31. PubMed ID: 24240684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells.
    Canino C; Mori F; Cambria A; Diamantini A; Germoni S; Alessandrini G; Borsellino G; Galati R; Battistini L; Blandino R; Facciolo F; Citro G; Strano S; Muti P; Blandino G; Cioce M
    Oncogene; 2012 Jun; 31(26):3148-63. PubMed ID: 22020330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
    Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
    Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation.
    Cioce M; Canino C; Goparaju C; Yang H; Carbone M; Pass HI
    Cell Death Dis; 2014 Apr; 5(4):e1167. PubMed ID: 24722292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.
    Gerogianni I; Pitaraki E; Jagirdar RM; Kouliou O; Giannakou L; Giannopoulos S; Papazoglou E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Anticancer Res; 2019 Jul; 39(7):3809-3814. PubMed ID: 31262908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma.
    Salaroglio IC; Belisario DC; Bironzo P; Ananthanarayanan P; Ricci L; Digiovanni S; Fontana S; Napoli F; Sandri A; Facolmatà C; Libener R; Comunanza V; Grosso F; Gazzano E; Leo F; Taulli R; Bussolino F; Righi L; Papotti MG; Novello S; Scagliotti GV; Riganti C; Kopecka J
    J Exp Clin Cancer Res; 2022 Feb; 41(1):75. PubMed ID: 35197103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesothelioma-Associated Fibroblasts Modulate the Response of Mesothelioma Patient-Derived Organoids to Chemotherapy via Interleukin-6.
    Cioce M; Gatti V; Napolitano F; Giorgiano NM; Marra A; Portella G; Fiorelli A; Pentimalli F; Fazio VM
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations.
    Canino C; Luo Y; Marcato P; Blandino G; Pass HI; Cioce M
    Oncotarget; 2015 May; 6(14):12637-53. PubMed ID: 25868979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-associated macrophage-derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma.
    Horio D; Minami T; Kitai H; Ishigaki H; Higashiguchi Y; Kondo N; Hirota S; Kitajima K; Nakajima Y; Koda Y; Fujimoto E; Negi Y; Niki M; Kanemura S; Shibata E; Mikami K; Takahashi R; Yokoi T; Kuribayashi K; Kijima T
    Cancer Sci; 2020 Aug; 111(8):2895-2906. PubMed ID: 32530527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with 
Malignant Pleural Mesothelioma].
    Zeng X; Jiang Z; Duan J
    Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
    Monica V; Lo Iacono M; Bracco E; Busso S; Di Blasio L; Primo L; Peracino B; Papotti M; Scagliotti G
    Oncotarget; 2016 Nov; 7(47):76577-76589. PubMed ID: 27391433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity.
    Cortes-Dericks L; Froment L; Boesch R; Schmid RA; Karoubi G
    BMC Cancer; 2014 Apr; 14():304. PubMed ID: 24884875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
    Zanellato I; Colangelo D; Osella D
    Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.
    Papazoglou ED; Jagirdar RM; Kouliou OA; Pitaraki E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds.
    Li Petri G; El Hassouni B; Sciarrillo R; Funel N; Mantini G; Zeeuw van der Laan EA; Cascioferro S; Avan A; Zucali PA; Zaffaroni N; Lagerweij T; Parrino B; Smid K; Deraco M; Granchi C; Braczko A; Smolenski RT; Matherly LH; Jansen G; Assaraf YG; Diana P; Cloos J; Peters GJ; Minutolo F; Giovannetti E
    Br J Cancer; 2020 Aug; 123(4):644-656. PubMed ID: 32493992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.
    Milosevic V; Kopecka J; Salaroglio IC; Libener R; Napoli F; Izzo S; Orecchia S; Ananthanarayanan P; Bironzo P; Grosso F; Tabbò F; Comunanza V; Alexa-Stratulat T; Bussolino F; Righi L; Novello S; Scagliotti GV; Riganti C
    Int J Cancer; 2020 Jan; 146(1):192-207. PubMed ID: 31107974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.
    Mairinger FD; Vollbrecht C; Flom E; Christoph DC; Schmid KW; Kollmeier J; Popper HH; Mairinger T; Walter RFH
    Oncotarget; 2017 Jun; 8(23):37502-37510. PubMed ID: 28415584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.